Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in need NORTH CHICAGO, Ill....
Hence then, the article about abbvie and gubra announce license agreement to develop an amylin analog for the treatment of obesity was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity )
Also on site :
- 2007 Grammy-Nominated Hit, Written by a 16-Year-Old After a Heated Argument, Became a Career-Defining Classic
- Bravo Fans Are Losing It Over Rumors ‘Summer House’s Lindsay Hubbard and ‘Below Deck’s Joe Bradley Kissed
- Prince Harry Says He ‘Slipped Into Depression’ After Moving to Canada in 2019, Just Before Stepping Back From Royal Duties